Clinical trials: Primary Glioblastoma
Glioblastoma Multiforme
FET-PET Directed Simultaneous In-field Boost for Primary GBM
The combination of anatomical MRI examination with functional examination of tissue metabolic activity such as FET-PET (PET using the radiotracer - 18F-fluoro-ethyl-tyrosine) is a valuable tool to determine the actual tumor…
- Trial name
- dualFETboost (NCT04790097)
- Testing
- Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost
- Where
- Poland
- Volunteers
- 17 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Glioblastoma Multiforme, Glioma
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors.
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02502708
- Testing
- Indoximod, Temozolomide, Conformal Radiation
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- NewLink Genetics Corporation
Newly Diagnosed Glioblastoma
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM) will be enrolled with the intent to receive an autologous dendritic cell vaccine consisting of…
- Trial name
- NCT03400917
- Testing
- AV-GBM-1
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Aivita Biomedical, Inc.
Glioblastoma Multiforme, Brain Metastases
PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
The purpose of this study is to evaluate diagnostic imaging techniques using 124I-NM404 PET/CT in human brain tumors. This goal will be accomplished by quantifying tumor uptake and determining the optimal PET/CT protocol…
- Trial name
- NCT01540513
- Testing
- NM404
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison